Tuesday, December 16, 2014 7:16:26 PM
As for the need to dip into the well and find more funding in the not-too-distant future, I don't really disagree. After resolving debts and some troublesome warrants, about $3-4M is left from the S-1. If revenues don't ramp up soon, money could run out in Q2. However, if indeed revenues begin to neutralize operating expenses as was mentioned, wouldn't we all be pleasantly surprised to see re-funding efforts become something of the past? This was simply the optimistic corner from the back of my mind talking, nothing that any management officials stated.
Like you, I am unhappy about recent events - stock decline, S-1 dilution with cheapened APDN shares and now the Q4 results. The unexpected lack of Q4 revenues was perhaps the most deflating surprise. But the CFO explained that some of the scheduled revenues fell into the deferred category and will be corrected in Q1, so this softened some of my disappointment. Putting Q4 aside and looking at the overall gain of revenues and contracting losses for 2014 v. 2013, I believe ADNAS stumbled in Q4 but is still headed in the right direction.
Most of us judge managerial performance by the company's stock price. By that standard management should have been fired long ago. However, my intuitions still contend that APDN still is not reflecting an accurate value of its true worth. The insiders are the largest block of stockholders. For all the suffering we have sustained, management has sustained proportionately more. That doesn't excuse their leadership but tries to place our combined situations into a fairer perspective.
I remain hopeful that APDN will make a turnaround. We have already been told that Q1 revenues will exceed $1M. When has management ever forecasted quarterly revenues before? Moreover, is $1M/Q the new standard? Can we anticipate $4M for 2015? Can we actually expect more than $4M for 2015 due to the announcements that 2 contracts should provide $4M over the next 2 years and that in the past no singular source of revenues exceeded 10% of the total revenues? From my perspective, the future looks brighter than it has ever looked before. All of this fuels my optimism.
GLTY & GLTA.
Recent APDN News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 10:18:33 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:25:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/12/2024 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:01:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:05:28 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:24:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 10:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:05:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/07/2023 09:01:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 10:09:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2023 10:02:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:05:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 08:02:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 09:04:44 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM